1525 Superior Avenue, Suite 200
Newport Beach, CA 92663
Phone (949) 650-0506
Fax (949) 999-8126

Receive our newsletter
  Home  
  Our Team  
  Patient Info  
  Contact Us  

News for Healthier Living

Diagnostic Technology Advancements for Neuroendocrine Tumor Mapping Resulted in Dramatic Shifts in Access to Theranostics Care

A new study from the Harvey L. Neiman Health Policy Institute found that the introduction of PET-based Gallium-68 DOTATATE/DOTATOC radiotracers for imaging neuroendocrine tumors created substantial differences in patient access during its first four years of use. Compared with the older imaging agent, Indium-111 pentetreotide (Octreoscan(tm)), patients in small-rural areas traveled 134.9 additional miles on average to access Gallium-68 DOTATATE/DOTATOC. By comparison, patients in metropolitan-micropolitan areas traveled only 26.7 additional miles. The study, published in the Journal of the American College of Radiology, analyzed 3,365 claims for neuroendocrine tumor radiotracers.

April 30, 2026


May 13 2026

May 12 2026

May 11 2026

May 10 2026

May 8 2026

May 7 2026

May 6 2026

May 5 2026

May 4 2026

May 1 2026

April 30 2026

April 29 2026